tradingkey.logo
tradingkey.logo
検索

Edwards Lifesciences Corp

EW
ウォッチリストに追加
87.360USD
+0.680+0.78%
終値 06/18, 16:00ET15分遅れの株価
50.30B時価総額
46.39直近12ヶ月PER

詳細情報 Edwards Lifesciences Corp 企業名

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Edwards Lifesciences Corpの企業情報

企業コードEW
会社名Edwards Lifesciences Corp
上場日Mar 27, 2000
最高経営責任者「CEO」Zovighian (Bernard J)
従業員数15800
証券種類Ordinary Share
決算期末Mar 27
本社所在地One Edwards Way
都市IRVINE
証券取引所NASDAQ OMX NASDAQ Basic NYSE
United States of America
郵便番号92614
電話番号19492502500
ウェブサイトhttps://www.edwards.com
企業コードEW
上場日Mar 27, 2000
最高経営責任者「CEO」Zovighian (Bernard J)

Edwards Lifesciences Corpの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
284.40K
+2.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
79.69K
+5.41%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
39.67K
+16.33%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
30.12K
+59.32%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
22.62K
+53.60%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.56K
+58.48%
Mr. Donald E. Bobo, Jr.
Mr. Donald E. Bobo, Jr.
Corporate Vice President - Strategy and Corporate Development
Corporate Vice President - Strategy and Corporate Development
--
--
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Ms. Leslie S. Heisz
Ms. Leslie S. Heisz
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
284.40K
+2.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
79.69K
+5.41%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
39.67K
+16.33%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
30.12K
+59.32%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
22.62K
+53.60%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.56K
+58.48%

よくある質問

Edwards Lifesciences Corpの上位5名の株主は誰ですか?

Edwards Lifesciences Corpの上位5名の株主は以下のとおりです。Mr. Scott B. Ullem

Edwards Lifesciences Corp(EW)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Edwards Lifesciences Corpの株式を保有している機関は2620社あり、保有株式の総市場価値は約539.60Mで、全体の93.71%を占めています。2025Q4と比較して、機関の持ち株は-12944884.00増加しています。

Edwards Lifesciences Corpの最大の収益源は何ですか?

2026Q1において、Transcatheter Aortic Valve Replacement部門がEdwards Lifesciences Corpにとって最大の収益を生み出しており、その金額は4.49Bで、全収益の73.96%を占めています。
KeyAI